A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants with Episodic Migraine

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512904-21-00

Acronym

D7060C00003(M26-031)

Enrollment

448

Registered

2024-11-19

Start date

2025-12-10

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

Change in number of MHDs from 4-week baseline to last 4 weeks of treatment period (Week 9 to Week 12)

Interventions

DRUGPlacebo to match MEDI0618

DRUGMEDI0618

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in number of MHDs from 4-week baseline to last 4 weeks of treatment period (Week 9 to Week 12)	—

Countries

Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026